Related Experiment Videos

Paroxysmal supraventricular tachycardia during theophylline therapy in a premature infant

Insights

Premature infants may experience supraventricular tachycardia when treated with theophylline. Monitoring theophylline levels is crucial to prevent serious adverse events and toxicity in neonates.

Area of Science:

  • Neonatal pharmacology
  • Pediatric cardiology
  • Clinical toxicology

Background:

  • Theophylline is a medication used for respiratory conditions in neonates.
  • Premature infants have immature metabolic pathways, affecting drug clearance.
  • Understanding theophylline pharmacokinetics is vital for safe and effective treatment.

Observation:

  • A 31-week premature infant developed supraventricular tachycardia during theophylline therapy.
  • The infant exhibited a prolonged theophylline half-life (24.7 hours) and low clearance (12.7 ml/kg/hour).
  • The plasma theophylline concentration reached approximately 42 mg/l at the time of the arrhythmia.

Findings:

  • Theophylline accumulation occurred due to the infant's immature drug metabolism.
  • High plasma theophylline concentrations correlated with the onset of supraventricular tachycardia.
  • The study highlights the risk of serious adverse effects with limited warning signs.

Implications:

  • Plasma theophylline concentration monitoring is essential for preventing toxicity in neonates.
  • Therapeutic drug monitoring can guide dose adjustments and mitigate risks.
  • This case underscores the importance of individualized dosing and pharmacokinetic assessment in premature infants.

Related Concept Videos